Isocitrate lyase: A potential target for anti-tubercular drugs

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 7, Issue 2, 2013, Pages 114-123

  Sharma, Rohit ^a   Das, Oisik ^a   Damle, Satyawan G ^a   Sharma, Anil K ^a  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

Author keywords

Inhibition; Isocitrate lyase; Mycobacterium tuberculosis; Persistence

Indexed keywords

1 CYCLOPROPYL 7 [3,5 DIMETHYL 4 (3 NITROPROPANOYL)PIPERAZIN 1 YL] 6 FLUORO 8 METHOXY 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 1,4 BUTANEDIOL; 2 PYRROLIDONE DERIVATIVE; 3 NITROPROPIONIC ACID; 4 CHLORO N [2 HYDROXY 4 (TRIFLUOROMETHYL)PHENYL] 2 METHOXYBENZOTHIOAMIDE; 5 CHLORO N (4 CHLORO 2 HYDROXYPHENYL) 2 METHOXYBENZAMIDE; 5 CHLORO N [2 HYDROXY 4 (TRIFLUOROMETHYL)PHENYL] 2 METHOXYBENZOTHIOAMIDE; ETHAMBUTOL; ISOCITRATE LYASE; ISONIAZID; KANAMYCIN; LYSINE; MALATE SYNTHASE; N (4 BROMO 2 HYDROXYPHENYL) 5 CHLORO 2 METHOXYBENZAMIDE; N (5 BROMO 2 HYDROXYPHENYL) 5 CHLORO 2 METHOXYBENZAMIDE; NICOTINIC ACID; RIBOFLAVIN; RIFAMPICIN; SALICYLANILIDE DERIVATIVE; STREPTOMYCIN; SUCCINIC ACID; TETRAHYDROFURAN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; BACTERIAL VIRULENCE; CITRIC ACID CYCLE; DRUG BLOOD LEVEL; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; INFECTION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PASTEURELLA; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DESIGN; HUMANS; ISOCITRATE LYASE; MICE; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; PATENTS AS TOPIC; TUBERCULOSIS;

EID: 84878624806     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872213X11307020003     Document Type: Review

References (70)

1. Ehrt S, Schnappinger D, Bekiranov S, Drenkow J, Shi S, Gingeras TR, et al. Reprogramming of the macrophage transcriptome in re sponse to interferon-gamma and Mycobacterium tuberculosis: Sig naling roles of nitric oxide synthase-2 and phagocyte oxidase. J Exp Med 2001; 194: 1123-1140.
2. Nathan C. Taming tuberculosis: A challenge for science and society. Cell Host Microbe 2009; 5(3): 220-224.
3. Nathan C, Gold B, Lin G, Stegman M, de Carvalho LP, Vandal O, et al. A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis. Tuberculosis 2008; 88 (Suppl 1): S25-S33.
4. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment. J Exp Med 2003; 198: 693-704.
5. Gautam R, Saklani A, Jachak SM. Indian medicinal plants as a source of antimycobacterial agents. J Ethnopharmacol 2007; 110(2): 200-234.
6. Mitchison DA. Treatment of tuberculosis. The Mitchell lecture 1979. JR Coll Physicians Lond 1980; 14(2): 98-99.
7. Girling DJ. The Biology of the Mycobacteria. In: Clinical Aspects of Mycobacterial Disease; Ratledge C, Stanford J, Grange JM. (Eds); Academic: London, 1989; Vol. 3.
8. Vanni P, Giachetti E, Pinzauti G, McFadden B. Comparative structure, function and regulation of isocitrate lyase, an important as-similatory enzyme Comp. Biochem Physiol B 1990; 95(3): 431-458.
9. Lorenz MC, Fink GR. Life and death in a macrophage: Role of the glyoxylate cycle in virulence. Eukaryot Cell 2002; 1: 657-662.
10. Vereecke D, Cornelis K, Temmerman W, Jaziri M, Montagu MV, Holsters M, et al. Chromosomal locus that affects pathogenicity of Rhodococcus fascians. J Bacteriol 2002; 184: 1112-1120.
11. Dunn MF, Ramirez-Trujillo JA, Hernandez-Lucas I. Major roles of isocitrate lyase and malate synthase in bacterial and fungal patho- genesis. Microbiology 2009; 155: 3166-3175.
12. Muñoz-Elías EJ, McKinney JD. M. tuberculosis isocitrate lyases 1 and 2 are jointly required for in-vivo growth and virulence. Nat Med 2005; 11(6): 638-644.
13. Solomon PS, Lee RC, Wilson TJG, Oliver RP. Pathogenicity of Stagonospora nodorum requires malate synthase. Mol Microbiol 2004; 53: 1065-1073.
14. Nakazawa M, Minami T, Teramura K, Kumamoto S, Hanato S, Takenaka S, et al. Molecular characterization of a bifunctional glyoxylate cycle enzyme, malate synthase/ isocitrate lyase, in Euglena gracilis. Comp Biochem Physiol B Biochem Mol Biol 2005; 141: 445-452.
15. Smith CV, Sharma V, Sacchettini JC. TB drug discovery: Addressing issues of persistence and resistance. Tuberculosis 2004; 84: 45-55.
16. Kumar R, Bhakuni V. Mycobacterium tuberculosis isocitrate lyase (MtbIcl): Role of divalent cations in modulation of functional and structural properties. Proteins 2008; 72(3): 892-900.
17. Kornberg HL, Krebs HA. Synthesis of cell constituents from C2-units by a modified tricarboxylic acid cycle. Nature 1957; 179: 988-991.
18. Kornberg HL, Madsen NB. Synthesis of C4-dicarboxylic acids from acetate by a glyoxylate bypass of the tricarboxylic acid cycle. Biochim Biophys Acta 1957; 24: 651-653.
19. Segal W, Bloch H. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J Bacteriol 1956; 72: 132-141.
20. Clark DP, Cronan JE Jr. in Escherichia coli and Salmonella: Cellular and Molecular Biology (ed. Neidhardt, F. C.) 1996; 343-357 (ASM Press, Washington DC).
21. Cronan JE Jr., LaPorte D. in Escherichia coli and Salmonella: Cellular and Molecular Biology (ed. Neidhardt, F. C.) 1996; 206-216 (ASM Press, Washington DC).
22. Wheeler PR, Ratledge C. in Tuberculosis: Pathogenesis, Protection, and Control (ed. Bloom, B. R.) 1994; 353-385 (ASM Press, Washington DC).
23. McKinney JD, Bentrup KHZ, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme iso-citrate lyase. Nature 2000; 406: 735-738.
24. Rees RJ, Hart PD. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br J Exp Pathol 1961; 42: 83-88.
25. Wallace JG. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Rev Respir Dis 1961; 83: 866-871.
26. Pelicic V, Jackson M, Reyart J-M, Jacobs WR, Gicquel B, Guilhot C. Effecient allelic exchange and transposon mutagenesis in Myco- bacterium tuberculosis. Proc Natl Acad Sci 1997; 94(20): 10955-10960.
27. Bentrup KHZ, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999; 181: 7161-7167.
28. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Micro-biol 2002; 43: 717-771.
29. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64: 2062-2069.
30. Nyka W. Studies on the effect of starvation on mycobacteria. Infect Immun 1974; 9: 843-850.
31. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and non human primates. Infect Immun 2008; 76: 2333-2340.
32. Lei J, Quanxin L, Dacheng Y, Jianping X. Identification of man-nich base as a novel inhibitor of Mycobacterium Tuberculosis iso-citrate by high-throughput screening. Int J Biol Sci 2011; 7(3): 376-382.
33. Bentrup KHZ, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999; 181: 7161-7167.
34. McFadden BA, Purohit S. Itaconate, an isocitrate lyasedirected inhibitor in Pseudomonas indigofera. J Bacteriol 1977; 131: 136-144.
35. Alston TA, Mela L, Bright HJ. 3-Nitropropionate, the toxic substance of Indigofera, is a suicide inactivator of succinate dehydro-genase. Proc Natl Acad Sci 1977; 74: 3767-3771.
36. Bai B, Xie J-P, Yan J-F, Wang H-H, Hu C-H. A high throughput screening approach to identify isocitrate lyase inhibitors from traditional Chinese medicine sources. Drug Dev Res 2007; 67: 818-823.
37. Sriram D, Yogeeswari D, Methuku S, Vyas DRK, Senthilkumar P, Alvala M, et al. Synthesis of various 3-nitropropionamides as My-cobacterium tuberculosis isocitrate lyase inhibitor. Bioorg Med Chem Lett 2011; 21: 5149-5154.
38. Xie Z, Siddiqi N, Rubin EJ. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother 2005; 49(11): 4778-4780.
39. Sriram D, Yogeeswari P, Vyas DRK, Senthilkumar P, Bhat P, Srividya M. 5-Nitro-2-furoic acid hydrazones: Design, synthesis and in vitro antimycobacterial evaluation against log and starved phase cultures. Bioorg Med Chem Lett 2010; 20: 4313-4316.
40. Sriram D, Yogeeswari P, Senthilkumar P, Naidu G, Bhat P. 5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: Synthesis and antimycobacterial activities. J Enzyme Inhib Med Chem 2010; 25: 765-772.
41. Sriram D, Yogeeswari P, Senthilkumar P, Sangaraju D, Nelli R, Banerjee D, et al. Synthesis and antimycobacterial evaluation of novel phthalazin-4-ylacetamides against log- and starved phase cultures. Chem Biol Drug Des 2010; 75: 381-391.
42. Sriram D, Yogeeswari P, Senthilkumar P, Dewakar S, Rohit N, Debjani B, et al. Novel pthalazinyl derivatives: Synthesis, antimy-cobacterial activities, and inhibition of Mycobacterium tuberculosis isocitrate lyase enzyme. Med Chem 2009; 5: 422-433.
43. Banerjee D, Yogeeswari P, Bhat P, Thomas A, Srividya, M, Sriram D.Novel isatinyl derivatives as potential molecule in the crusade against HIV-TB co-infection. Eur J Med Chem 2011; 46: 106-121.
44. Zwolska Z, Augustynowicz KE, Niemirowska MH. The pharma-cokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule. Acta Poloniae Pharmaceu-tica 2002; 59: 448-452.
45. Hearn MJ, Cynamon MH. Design and synthesis of antituberculars: Preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base. J Antimicrob Chemother 2004; 53(2): 185-191.
46. Hearn MJ, Cynamon MH, Chen MF, Coppins R, Davis J, Kang HJ-O, et al. Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid. Eur J Med Chem 2009; 44(10): 4169-4178.
47. Ito K, Yamamoto K, Kawanishi S. Manganese-mediated oxidative damage of cellular and isolated DNA by isoniazid and related hydrazines: Non-Fenton-type hydroxyl radical formation. Biochem 1992; 31(46): 11606-11613.
48. Voyatzakis VA, Vasilikiotis GS, Karageorgiou G, Kassapoglou I. Influence of metallic ions on the antituberculous activity of isoni-cotinoyl hydrazones. J Pharm Sci 1968; 57(7): 1255-1257.
49. Bottari B, Maccari R, Monforte F, Ottana R, Vigorita MG, Bruno G, et al. Nickel(II) 2,6-diacetylpyridine bis(isonicotinoyl-hydrazonate) and bis(benzoylhydrazonate) complexes: Structure and antimycobacterial evaluation. Part XI. Bioorg Med Chem Lett 2001; 9(8): 2203-2211.
50. Shingnapurkar D, Dandawate P, Anson CE, Powell AK, Afrasiabi Z, Sinn E, et al. Synthesis and characterization of pyruvate-isoniazid analogsand their copper complexes as potential ICL inhibitors. Bioorg Med Chem Letters 2012; 22: 3172-3176.
51. Kratky M, Vinsova J. Salicylanilide ester prodrugs as potential antimicrobial agents - a review. Curr Pharm Des 2011; 17(32): 3494-3505.
52. Hlasta DJ, Demers JP, Foleno BD, Fraga-Spano SA, Guan JH, Hilliard JJ, et al. Novel inhibitors of bacterial two-component systems with gram positive antibacterial activity: Pharmacophore identification based on the screening hit closantel. Bioorg Med Chem Lett 1998; 8(14): 1923-1928.
53. Macielag MJ, Demers JP, Fraga-Spano SA, Hlasta DJ, Johnson SG, Kanojia RM, et al. Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteria. J Med Chem 1998; 41(16): 2939-2945.
54. Waisser K, Bures O, Holy P, Kunes J, Oswald R, Jiraskova L, et al. Relationship between the structure and antimycobacterial activity of substituted salicylanilides. Arch Pharm 2003; 336(1): 53-71.
55. Waisser K, Matyk J, Divisova H, Husakova P, Kunes J, Klimesova V, et al. The oriented development of antituberculotics: Salicylanilides. Arch Pharm 2006; 339(11): 616-620.
56. Krátky M, Vinsová J, Novotná E, Mandíková J, Wsól V, Trejtnar F, et al. Salicylanilide derivatives block Mycobacterium tuberculosis through inhibition of isocitrate lyase and methionine aminopep-tidase. Tuberculosis (Edinb) 2012; 92(5): 434-439.
57. Desai KR, Shaikh MS, Coutinho EC. Molecular modeling studies, synthesis and biological evaluation of derivatives of N-phenylbenzamide as Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. Med Chem Res 2011; 20(3): 321-332.
58. Ertan T, Yildiz I, Ozkan S, Temiz-Arpaci O, Kaynak F, Yalcin I, et al. Synthesis and biological evaluation of new N-(2-hydroxy-4(or 5) nitro/aminophenyl)benzamides and phenylacetamides as antimicrobial agents. Bioorgan Med Chem Lett 2007; 15(5): 2032-2044.
59. Kozic J, Novotná E, Volková M, Stolaríková J, Trejtnar F, Vinsová J. Synthesis and in vitro antimycobacterial activity of 2 -methoxybenzanilides and their thioxo analogues. Eur J Med Chem 2012; 56: 387-395.
60. Kozic J, Novotná E, Volková M, Stolaríková J, Trejtnar F, Vladimir W, et al. Synthesis and in vitro antimycobacterial and isocitrate lyase inhibition properties of novel 2-methoxy-2-hydroxybenzanilides, their thioxo analogues and benzoxazoles. Eur J Med Chem 2012; 56: 108-119.
61. Sacchettini, J.C., Jacobs, W.R., Russell, D.G., McKinney, J.D., Sharma, V., Sharma, S., Kerstin, A., Honerzu, B.H. Structure of isocitrate lyase enzyme from Mycobacterium tuberculosis and inhibitory agents to combat persistent infection. US20030018166 (2003).
62. McKinney, J.D., Jacobs, Jr. W.R. Mycobacterial isocitrate lyase gene and uses thereof. US6387694 (2002) & US6733761 (2004).
63. Bathe, B., Kreutzer, C, Hans, S. Alleles of the aceA gene from coryneform bacteria. US708394 (2006).
64. Valletta, G. Use of vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation. US007026319 (2006).
65. Kasler, B., Sahm, H., Stahmann, K.P., Schmidt, G., Boddecker, T., Seulberger, H. Use of vitamin combination for the treatment of pruritus and non-infective disorders involving itching and/or inflammation. US005976844 (1999).
66. Balganesh, T.S., Datta, S., Ghosh, I. Method. US20080261240 (2008).
67. Bestel-Corre, G., Figge, R., Raynaud, C., Soucaille, P. Process for the prepration of a aspartate and derived amino acids like lysine, threonine, isoleucine, methionine or homoserine employing microorganism with enhanced isocitrate lyase and/or malate synthase expression. US20080233617 (2008).
68. Haefner, S., Scholten, E., Schroder, H. Bacterial cells having a glyoxylate shunt for the manufacture of succinic acid. US20100159543 (2010).
69. Dhamankar, H.H., Martin, C.H., Prather, K.L.J. Microbial production of 3,4-dihydroxybutyrate (3,4-DHBA), 2,3-dihydroxybutrate (2,3-DHBA) and3-hydroxybutyrolactone(3-HBL). US20120226055 (2012).
70. D'elia, J.N., Jordan, S.W. Altered glyoxylate shunt for improved production of aspartate-derived amino acids and chemicals. US8187842 (2012).